TLSA
Tiziana Life Sciences Ltd
Price Chart
Latest Quote
$1.06
-0.02 (-1.85%)
Current Price
| Previous Close | $1.08 |
| Open | $1.10 |
| Day High | $1.11 |
| Day Low | $1.06 |
| Volume | 38,990 |
Stock Information
| Shares Outstanding | 127.26M |
| Total Debt | $456K |
| Cash Equivalents | $4.01M |
| Net Income | $-18.43M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $134.89M |
| EPS (TTM) | $-0.16 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $129.00M |
| Income | $-18.43M |
| Book/sh | $0.08 |
| Cash/sh | $0.03 |
| Employees | 10 |
Financial Ratios
| Quick Ratio | 0.72 |
| Current Ratio | 0.76 |
| Debt/Eq | 876.92 |
Returns & Margins
| ROA | -115.96% |
| ROE | -924.32% |
Ownership
| Insider Ownership | 43.48% |
| Institutional Ownership | 2.94% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.31 |
| P/B | 13.77 |
Analyst Data
| Recommendation | none |
| Target Price | $8.89 |
Technical Indicators
| SMA20 | $1.27 |
| SMA50 | $1.32 |
| SMA200 | $1.55 |
| RSI | 18.18 |
| ATR | 0.0964 |
| Shares Float | 64.00M |
| Short Float | 4.02% |
| Short Ratio | 6.18 |
| Volatility | 0.42 |
| Rel Volume | 0.14 |
Performance History
| Week | -6.19% |
| Month | -23.19% |
| Quarter | -15.87% |
| 6 Months | -31.61% |
| YTD | -33.75% |
| Year | -35.76% |
| 3 Years | +39.47% |
| 5 Years | -57.43% |
| 10 Years | -36.55% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.06 | 38,990 |
| 2026-06-17 | $1.08 | 267,700 |
| 2026-06-16 | $1.10 | 112,200 |
| 2026-06-15 | $1.11 | 276,200 |
| 2026-06-12 | $1.10 | 423,500 |
| 2026-06-11 | $1.13 | 349,100 |
| 2026-06-10 | $1.16 | 132,700 |
| 2026-06-09 | $1.22 | 132,600 |
| 2026-06-08 | $1.22 | 118,800 |
| 2026-06-05 | $1.24 | 84,300 |
| 2026-06-04 | $1.27 | 196,700 |
| 2026-06-03 | $1.18 | 646,600 |
| 2026-06-02 | $1.36 | 167,700 |
| 2026-06-01 | $1.40 | 114,600 |
| 2026-05-29 | $1.41 | 228,100 |
| 2026-05-28 | $1.46 | 249,100 |
| 2026-05-27 | $1.47 | 259,900 |
| 2026-05-26 | $1.51 | 191,200 |
| 2026-05-22 | $1.48 | 575,600 |
| 2026-05-21 | $1.46 | 1,146,000 |
| 2026-05-20 | $1.61 | 276,300 |
| 2026-05-19 | $1.38 | 247,000 |
| 2026-05-18 | $1.35 | 80,000 |
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
đ° Latest News
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Motley Fool âĸ 2026-05-29T22:55:31Z
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data â ICYMI
Proactive âĸ 2026-05-22T20:48:00Z
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
Proactive âĸ 2026-05-21T15:44:00Z
Sector Update: Healthcare Stocks Gain Late Afternoon
MT Newswires âĸ 2026-05-19T19:55:35ZTiziana Life Sciences price target boosted on foralumab update
Proactive âĸ 2026-05-19T19:12:00Z
Sector Update: Healthcare Stocks Rise Tuesday Afternoon
MT Newswires âĸ 2026-05-19T18:02:34ZTiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS
Proactive âĸ 2026-05-19T13:42:00Z
Tiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trial
Proactive âĸ 2026-05-14T13:06:00Z
Inventiva Builds Up Leadership Team Ahead of Potential Commercialization
Exec Edge âĸ 2026-04-22T22:03:19Z
Tiziana says intranasal drug shows potential to ease Long COVID âbrain fogâ
Proactive âĸ 2026-04-16T12:58:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | - | - | - |
| Cost Of Revenue | - | - | - | - |
| Expenses | ||||
| Interest Expense | $18,000 | $6,000 | $10,000 | $38,000 |
| Total Expenses | $21,132,000 | $15,794,000 | $17,984,000 | $14,586,000 |
| Other Income Expense | $2,700,000 | $-1,760,000 | $-402,000 | $-804,000 |
| Net Non Operating Interest Income Expense | $1,000 | $808,000 | $1,144,000 | $-6,000 |
| Interest Expense Non Operating | $18,000 | $6,000 | $10,000 | $38,000 |
| Operating Expense | $21,132,000 | $15,794,000 | $17,984,000 | $14,586,000 |
| Other Operating Expenses | $10,853,000 | $10,565,000 | $9,871,000 | $1,631,000 |
| Other Non Operating Income Expenses | - | - | - | $65,000 |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-18,431,000 | $-11,863,000 | $-17,691,000 | $-15,397,000 |
| Net Interest Income | $1,000 | $808,000 | $1,144,000 | $-6,000 |
| Interest Income | $19,000 | $814,000 | $1,154,000 | $32,000 |
| Normalized Income | $-21,131,000 | $-10,616,202 | $-17,373,420 | $-14,528,000 |
| Net Income From Continuing And Discontinued Operation | $-18,431,000 | $-11,863,000 | $-17,691,000 | $-15,397,000 |
| Total Operating Income As Reported | $-21,132,000 | $-15,794,000 | $-17,984,000 | $-14,586,000 |
| Net Income Common Stockholders | $-18,431,000 | $-11,863,000 | $-17,691,000 | $-15,397,000 |
| Net Income | $-18,431,000 | $-11,863,000 | $-17,691,000 | $-15,397,000 |
| Net Income Including Noncontrolling Interests | $-18,431,000 | $-11,863,000 | $-17,691,000 | $-15,397,000 |
| Net Income Continuous Operations | $-18,431,000 | $-11,863,000 | $-17,691,000 | $-15,397,000 |
| Pretax Income | $-18,431,000 | $-16,746,000 | $-17,242,000 | $-15,397,000 |
| Interest Income Non Operating | $19,000 | $814,000 | $1,154,000 | $32,000 |
| Operating Income | $-21,132,000 | $-15,794,000 | $-17,984,000 | $-14,586,000 |
| Special Income Charges | - | - | - | $0 |
| Gross Profit | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-0.16 | $-0.11 | $-0.17 | $-0.15 |
| Basic EPS | $-0.16 | $-0.11 | $-0.17 | $-0.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-513,202 | $-84,420 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-20,879,000 | $-14,856,000 | $-16,734,000 | $-14,439,000 |
| Total Unusual Items | $2,700,000 | $-1,760,000 | $-402,000 | $-869,000 |
| Total Unusual Items Excluding Goodwill | $2,700,000 | $-1,760,000 | $-402,000 | $-869,000 |
| Reconciled Depreciation | $234,000 | $124,000 | $96,000 | $51,000 |
| EBITDA (Bullshit earnings) | $-18,179,000 | $-16,616,000 | $-17,136,000 | $-15,308,000 |
| EBIT | $-18,413,000 | $-16,740,000 | $-17,232,000 | $-15,359,000 |
| Diluted Average Shares | $118,282,753 | $106,672,342 | $102,471,016 | $101,526,389 |
| Basic Average Shares | $118,282,753 | $106,672,342 | $102,471,016 | $101,526,389 |
| Diluted NI Availto Com Stockholders | $-18,431,000 | $-11,863,000 | $-17,691,000 | $-15,397,000 |
| Tax Provision | $0 | $-4,883,000 | $449,000 | $0 |
| Gain On Sale Of Security | $2,700,000 | $-1,760,000 | $-402,000 | $-869,000 |
| Research And Development | $10,279,000 | $5,229,000 | $8,113,000 | $12,955,000 |
| Selling General And Administration | - | - | $0 | $0 |
| Salaries And Wages | - | - | $0 | $0 |
| Gain On Sale Of Ppe | - | - | - | $0 |
| Write Off | - | - | - | $0 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $52,000 | $3,936,000 | $5,536,000 | $19,571,000 |
| Total Assets | $11,495,000 | $11,284,000 | $12,184,000 | $26,477,000 |
| Total Non Current Assets | $2,943,000 | $3,776,000 | $4,847,000 | $2,195,000 |
| Current Assets | $8,552,000 | $7,508,000 | $7,337,000 | $24,282,000 |
| Prepaid Assets | $285,000 | $92,000 | $102,000 | $170,000 |
| Receivables | $4,257,000 | $3,692,000 | $6,052,000 | $5,990,000 |
| Other Receivables | $174,000 | $53,000 | $121,000 | $130,000 |
| Taxes Receivable | $99,000 | $32,000 | $3,793,000 | $4,246,000 |
| Cash Cash Equivalents And Short Term Investments | $4,010,000 | $3,724,000 | $1,183,000 | $18,122,000 |
| Cash And Cash Equivalents | $4,010,000 | $3,724,000 | $1,183,000 | $18,122,000 |
| Goodwill And Other Intangible Assets | - | - | $0 | $0 |
| Non Current Accounts Receivable | - | - | - | - |
| Hedging Assets Current | - | - | - | - |
| Debt | ||||
| Total Debt | $456,000 | $106,000 | $247,000 | $365,000 |
| Long Term Debt And Capital Lease Obligation | $234,000 | $0 | $109,000 | $243,000 |
| Current Debt And Capital Lease Obligation | $222,000 | $106,000 | $138,000 | $122,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $11,443,000 | $7,348,000 | $6,648,000 | $6,906,000 |
| Total Non Current Liabilities Net Minority Interest | $234,000 | $0 | $109,000 | $243,000 |
| Current Liabilities | $11,209,000 | $7,348,000 | $6,539,000 | $6,663,000 |
| Other Current Liabilities | $-3,000 | $12,000 | $14,000 | $9,000 |
| Current Deferred Liabilities | $530,000 | $0 | - | - |
| Payables And Accrued Expenses | $10,460,000 | $7,230,000 | $6,387,000 | $6,532,000 |
| Payables | $7,173,000 | $5,580,000 | $4,137,000 | $4,962,000 |
| Accounts Payable | $7,173,000 | $5,580,000 | $4,137,000 | $4,962,000 |
| Equity | ||||
| Common Stock Equity | $52,000 | $3,936,000 | $5,536,000 | $19,571,000 |
| Total Equity Gross Minority Interest | $52,000 | $3,936,000 | $5,536,000 | $19,571,000 |
| Stockholders Equity | $52,000 | $3,936,000 | $5,536,000 | $19,571,000 |
| Other Equity Interest | $11,476,000 | $8,561,000 | $7,130,000 | $5,887,000 |
| Gains Losses Not Affecting Retained Earnings | $116,901,000 | $116,990,000 | $117,061,000 | $115,569,000 |
| Other Equity Adjustments | $118,697,000 | $118,697,000 | $118,697,000 | $118,697,000 |
| Retained Earnings | $-163,109,000 | $-144,831,000 | $-133,676,000 | $-116,263,000 |
| Long Term Equity Investment | $2,444,000 | $3,589,000 | $4,554,000 | $1,806,000 |
| Other | ||||
| Ordinary Shares Number | $120,507,401 | $111,462,617 | $101,514,234 | $100,589,070 |
| Share Issued | $120,507,401 | $111,462,617 | $103,087,744 | $102,272,614 |
| Tangible Book Value | $52,000 | $3,936,000 | $5,536,000 | $19,571,000 |
| Invested Capital | $52,000 | $3,936,000 | $5,536,000 | $19,571,000 |
| Working Capital | $-2,657,000 | $160,000 | $798,000 | $17,619,000 |
| Capital Lease Obligations | $456,000 | $106,000 | $247,000 | $365,000 |
| Total Capitalization | $52,000 | $3,936,000 | $5,536,000 | $19,571,000 |
| Foreign Currency Translation Adjustments | $-1,796,000 | $-1,707,000 | $-1,636,000 | $-3,128,000 |
| Additional Paid In Capital | $34,663,000 | $23,105,000 | $16,492,000 | $15,596,000 |
| Capital Stock | $121,000 | $111,000 | $103,000 | $102,000 |
| Common Stock | $121,000 | $111,000 | $103,000 | $102,000 |
| Long Term Capital Lease Obligation | $234,000 | $0 | $109,000 | $243,000 |
| Current Deferred Revenue | $530,000 | $0 | - | - |
| Current Capital Lease Obligation | $222,000 | $106,000 | $138,000 | $122,000 |
| Current Accrued Expenses | $3,287,000 | $1,650,000 | $2,250,000 | $1,570,000 |
| Investments And Advances | $2,444,000 | $3,589,000 | $4,554,000 | $1,806,000 |
| Net PPE | $499,000 | $187,000 | $293,000 | $389,000 |
| Gross PPE | $499,000 | $187,000 | $293,000 | $389,000 |
| Other Properties | $499,000 | $187,000 | $293,000 | $389,000 |
| Duefrom Related Parties Current | $3,984,000 | $3,607,000 | $2,138,000 | $1,614,000 |
| Treasury Shares Number | - | $0 | $1,573,510 | $1,683,544 |
| Treasury Stock | - | $0 | $1,574,000 | $1,320,000 |
| Dueto Related Parties Current | - | - | - | $0 |
| Accumulated Depreciation | - | - | - | - |
| Machinery Furniture Equipment | - | - | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,868,000 | $-1,545,000 | $-15,698,000 | $-19,615,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,847,000 | $-1,526,000 | $-15,698,000 | $-19,615,000 |
| Cash Flow From Continuing Operating Activities | $-12,847,000 | $-1,526,000 | $-15,698,000 | $-19,615,000 |
| Operating Gains Losses | $-152,000 | $159,000 | $1,519,000 | $-3,054,000 |
| Investing Activities | ||||
| Capital Expenditure | $-21,000 | $-19,000 | - | - |
| Investing Cash Flow | $3,043,000 | $-71,000 | $-1,253,000 | $-3,996,000 |
| Cash Flow From Continuing Investing Activities | $3,043,000 | $-71,000 | $-1,253,000 | $-3,996,000 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $10,059,000 | $4,571,000 | $24,000 | $0 |
| Financing Cash Flow | $10,006,000 | $4,505,000 | $40,000 | $-55,000 |
| Cash Flow From Continuing Financing Activities | $10,006,000 | $4,505,000 | $40,000 | $-55,000 |
| Net Common Stock Issuance | $10,059,000 | $4,571,000 | $24,000 | $0 |
| Common Stock Issuance | $10,059,000 | $4,571,000 | $24,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-196,000 | $-141,000 | $-119,000 | $-55,000 |
| End Cash Position | $4,010,000 | $3,724,000 | $1,183,000 | $18,122,000 |
| Beginning Cash Position | $3,724,000 | - | - | - |
| Effect Of Exchange Rate Changes | $84,000 | $-367,000 | $-28,000 | $-398,000 |
| Changes In Cash | $202,000 | $2,908,000 | $-16,911,000 | $-23,666,000 |
| Proceeds From Stock Option Exercised | $143,000 | $75,000 | $135,000 | $0 |
| Net Issuance Payments Of Debt | $-196,000 | $-141,000 | $-119,000 | $-55,000 |
| Net Long Term Debt Issuance | $-196,000 | $-141,000 | $-119,000 | $-55,000 |
| Long Term Debt Payments | $-196,000 | $-141,000 | $-119,000 | $-55,000 |
| Net Investment Purchase And Sale | $3,064,000 | $-52,000 | $-1,253,000 | $-3,996,000 |
| Sale Of Investment | $3,064,000 | $0 | $0 | - |
| Purchase Of Investment | $0 | $-52,000 | $-1,253,000 | $-3,996,000 |
| Net PPE Purchase And Sale | $-21,000 | $-19,000 | $0 | $0 |
| Purchase Of PPE | $-21,000 | $-19,000 | $0 | $0 |
| Taxes Refund Paid | $-75,000 | $8,784,000 | $0 | $490,000 |
| Change In Working Capital | $3,062,000 | $-552,000 | $-1,582,000 | $-1,164,000 |
| Change In Other Working Capital | $530,000 | - | - | - |
| Change In Other Current Liabilities | $3,224,000 | $839,000 | $-138,000 | $347,000 |
| Change In Other Current Assets | $-314,000 | $78,000 | $80,000 | $1,002,000 |
| Change In Payables And Accrued Expense | $0 | $0 | $0 | $-1,355,000 |
| Change In Account Payable | $0 | $0 | $0 | $-1,355,000 |
| Change In Receivables | $-378,000 | $-1,469,000 | $-1,524,000 | $-1,158,000 |
| Other Non Cash Items | $3,126,000 | $3,516,000 | $-625,000 | - |
| Stock Based Compensation | $1,141,000 | $1,429,000 | $1,734,000 | $-1,410,000 |
| Unrealized Gain Loss On Investment Securities | $-1,752,000 | $1,760,000 | $402,000 | $869,000 |
| Depreciation Amortization Depletion | $234,000 | $124,000 | $96,000 | $51,000 |
| Depreciation And Amortization | $234,000 | $124,000 | $96,000 | $51,000 |
| Depreciation | $234,000 | $124,000 | $96,000 | $51,000 |
| Net Foreign Currency Exchange Gain Loss | $-152,000 | $158,000 | $1,519,000 | $-3,183,000 |
| Net Income From Continuing Operations | $-18,431,000 | $-16,746,000 | $-17,242,000 | $-15,397,000 |
| Gain Loss On Sale Of PPE | - | - | $0 | $0 |
| Issuance Of Debt | - | - | - | $0 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
| Change In Payable | - | - | - | $-1,355,000 |
| Asset Impairment Charge | - | - | - | $0 |
Fetched: 2026-06-17